OTCMKTS:NVZMY - NOVOZYMES A/S/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 8
  • Breakdown:
  • 5 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$62.05
▼ -0.2 (-0.32%)
1 month | 3 months | 12 months
Get New NOVOZYMES A/S/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVZMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVZMY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for NOVOZYMES A/S/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $62.05.
Hold
The current consensus among 8 polled investment analysts is to hold stock in NOVOZYMES A/S/S.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 3 sell ratings
5/6/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 3 sell ratings
8/4/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 3 sell ratings
11/2/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 3 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 3 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 6 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 6 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 5 sell ratings
10/27/2020

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 5 sell ratings

DateBrokerageActionRatingPrice TargetDetails
10/8/2020Berenberg BankDowngradeHold ➝ Sell
i
10/1/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
i
8/13/2020BarclaysReiterated RatingUnderweight
i
7/28/2020BarclaysInitiated CoverageUnderweight
i
7/8/2020UBS GroupReiterated RatingSell
i
7/2/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
i
5/12/2020Credit Suisse GroupDowngradeOutperform ➝ Underperform
i
4/1/2020Goldman Sachs GroupDowngradeBuy ➝ Sell
i
1/14/2020BNP ParibasDowngradeOutperform ➝ Neutral
i
1/7/2020Goldman Sachs GroupInitiated CoverageBuy
i
12/17/2019Berenberg BankDowngradeBuy ➝ Hold
i
11/20/2019CitigroupUpgradeNeutral ➝ Buy
i
9/30/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
8/19/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
3/26/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
2/12/2019Bank of AmericaInitiated CoverageBuy ➝ Buy
i
2/5/2019Berenberg BankUpgradeHold ➝ Buy
i
1/30/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
1/28/2019Goldman Sachs GroupUpgradeSell ➝ Neutral
i
12/20/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
10/30/2018JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
3/5/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
10/26/2017Jefferies Financial GroupReiterated RatingHold$54.97
i
Rating by Akshay Jagdale at Jefferies Financial Group Inc.
8/14/2017Jefferies Financial GroupSet Price TargetHold$48.00
i
Rating by Akshay Jagdale at Jefferies Financial Group Inc.
5/10/2017Jefferies Financial GroupReiterated RatingHold$47.50
i
5/9/2017Jefferies Financial GroupReiterated RatingHold$47.50
i
2/10/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
2/1/2017Goldman Sachs GroupDowngradeNeutral ➝ Sell
i
1/5/2017Sanford C. BernsteinUpgradeMkt Perform ➝ Outperform
i
12/9/2016JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
11/1/2016Berenberg BankUpgradeSell ➝ Hold
i
10/7/2016Deutsche Bank AktiengesellschaftInitiated CoverageHold
i
9/27/2016Berenberg BankInitiated CoverageSell
i
1/20/2016Goldman Sachs GroupUpgradeSell ➝ Neutral
i
(Data available from 10/27/2015 forward)
NOVOZYMES A/S/S logo
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising bioscouring, bleach clean-up, desizing, denim finishing and abrasion, and biopolishing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rtrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research and development, production, marketing, and sale of a portfolio of probiotic products. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Read More

Today's Range

Now: $62.05
$61.59
$62.13

50 Day Range

MA: $63.70
$60.52
$65.98

52 Week Range

Now: $62.05
$37.99
$66.75

Volume

7,113 shs

Average Volume

38,026 shs

Market Capitalization

$18.43 billion

P/E Ratio

39.52

Dividend Yield

0.84%

Beta

0.57